Blog

Maximizing oligonucleotide therapeutic development: Pre-clinical and translational considerations

This is the second of three blog posts discussing best practices for developing oligonucleotide therapeutics.…

Certara2021 年 6 月 25 日

Press Coverage

Fundamentals of regulatory writing: the document development process

Regulatory writers lead the development of high-quality regulatory documents by working incollaboration with colleagues across…

Certara2021 年 6 月 22 日

Blog

Preparing for high stakes meetings; how to best convey a new drug’s value to payers

This blog post includes key takeaways from the opening session of Certara’s first Strategic Evidence…

Certara2021 年 6 月 18 日

Blog

Watershed moment for the future of cell therapy development – FDA advisory committee meeting

Every FDA Advisory Committee meeting is unique, and the Cellular, Tissue, and Gene Therapies Advisory…

Certara2021 年 6 月 15 日

Brochure

推动具有影响力的科学成果从实验室走向市场

Learn how Certara drives impactful science.

Certara2021 年 6 月 14 日

On-Demand Webinar

Three Pathways have emerged in Innovative Access Agreements

The days of simply determining the market demand for a new drug as a function…

Certara2021 年 6 月 11 日

On-Demand Webinar

Outcomes Based Agreements

The days of simply determining the market demand for a new drug as a function…

Certara2021 年 6 月 11 日

Video

Your First Choice in Complex Biologics Drug Development

The pharmaceutical has made massive investments in complex biologics, a drug class that includes oligonucleotide…

Certara2021 年 6 月 1 日

On-Demand Webinar

利用基于证据的次要药效学信息降低项目风险

Safety issues account for about a quarter of the attrition in drug projects and can…

Certara2021 年 5 月 28 日

On-Demand Webinar

Stakeholder perspectives: current and potential benefits

Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…

Certara2021 年 5 月 26 日

pre-update

Maximizing oligonucleotide therapeutic development: Pre-clinical and translational considerations

Fundamentals of regulatory writing: the document development process

Preparing for high stakes meetings; how to best convey a new drug’s value to payers

Watershed moment for the future of cell therapy development – FDA advisory committee meeting

推动具有影响力的科学成果从实验室走向市场

Three Pathways have emerged in Innovative Access Agreements

Outcomes Based Agreements

Your First Choice in Complex Biologics Drug Development

利用基于证据的次要药效学信息降低项目风险

Stakeholder perspectives: current and potential benefits

订阅时事通讯

快捷链接

解决方案

联系我们